ACADIA Pharmaceuticals Inc. (ACAD): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

ACADIA Pharmaceuticals ( ACAD) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.8%. By the end of trading, ACADIA Pharmaceuticals fell $0.21 (-1.6%) to $13.19 on average volume. Throughout the day, 3,554,549 shares of ACADIA Pharmaceuticals exchanged hands as compared to its average daily volume of 3,492,400 shares. The stock ranged in price between $13.07-$13.92 after having opened the day at $13.40 as compared to the previous trading day's close of $13.40. Other companies within the Drugs industry that declined today were: Auxilium Pharmaceuticals ( AUXL), down 12.7%, Lexicon Pharmaceuticals ( LXRX), down 11.0%, Aastrom Biosciences ( ASTM), down 10.9% and Catalyst Pharmaceutical Partners ( CPRX), down 7.3%.
  • EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. ACADIA Pharmaceuticals has a market cap of $1.1 billion and is part of the health care sector. Shares are up 187.5% year to date as of the close of trading on Friday.

TheStreet Ratings rates ACADIA Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, weak operating cash flow and feeble growth in its earnings per share.

On the positive front, Galectin Therapeutics ( GALT), down 20.0%, Nymox Pharmaceutical Corporation ( NYMX), down 13.2%, Cardium Therapeutics ( CXM), down 12.4% and Oramed Pharmaceuticals ( ORMP), down 10.8% , were all gainers within the drugs industry with Allergan ( AGN) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.
null

If you liked this article you might like

Biotech M&A: Who's Next After Gilead-Kite?

'Longing' for Acadia Pharmaceuticals? Here's How to Play It

3 Housing Plays With Solid Earnings

7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods

Jana Partners Liquidates Whole Foods Stake After Engineering Industry-Transforming Sale To Amazon